{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T20:39:03Z","timestamp":1788381543354,"version":"build-2803163510"},"reference-count":55,"publisher":"Elsevier BV","issue":"7-8","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer\/Radioth\u00e9rapie"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.canrad.2025.104712","type":"journal-article","created":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T14:40:52Z","timestamp":1757515252000},"page":"104712","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Role of radiotherapy in the management of testicular cancer: Recommendations from the French society for radiation oncology"],"prefix":"10.1016","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-0526-8632","authenticated-orcid":false,"given":"Charles","family":"Raynaud","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2094-1708","authenticated-orcid":false,"given":"St\u00e9phane","family":"Supiot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Le Gu\u00e9velou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Blanchard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jihane","family":"Boustani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilien","family":"Rog\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guilhem","family":"Roubaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0045-6003","authenticated-orcid":false,"given":"Vincent","family":"Marchesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5935-5218","authenticated-orcid":false,"given":"Igor","family":"Latorzeff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Sargos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canrad.2025.104712_bib0280","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1002\/ijc.21032","article-title":"Epidemiology of testicular cancer: an overview","volume":"116","author":"Garner","year":"2005","journal-title":"Int J Cancer"},{"key":"10.1016\/j.canrad.2025.104712_bib0285","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.eururo.2019.07.002","article-title":"International trends in the incidence of testicular cancer: lessons from 35 years and 41 countries","volume":"76","author":"Gurney","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.canrad.2025.104712_bib0290","doi-asserted-by":"crossref","first-page":"e66","DOI":"10.1097\/PAS.0000000000001465","article-title":"Report from the International Society of Urological Pathology (ISUP) consultation conference on molecular pathology of urogenital cancers","volume":"44","author":"Looijenga","year":"2020","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.canrad.2025.104712_bib0295","doi-asserted-by":"crossref","first-page":"e12390","DOI":"10.1097\/MD.0000000000012390","article-title":"Recent global trends in testicular cancer incidence and mortality","volume":"97","author":"Park","year":"2018","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.canrad.2025.104712_bib0300","doi-asserted-by":"crossref","first-page":"13889","DOI":"10.1038\/srep13889","article-title":"Quantifying the heritability of testicular germ cell tumour using both population-based and genomic approaches","volume":"5","author":"Litchfield","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.canrad.2025.104712_bib0305","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1001\/jamaoncol.2018.6477","article-title":"Association of inherited pathogenic variants in checkpoint kinase 2 (CHEK2) with susceptibility to testicular germ cell tumors","volume":"5","author":"AlDubayan","year":"2019","journal-title":"JAMA Oncol"},{"issue":"9","key":"10.1016\/j.canrad.2025.104712_bib0310","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1001\/jama.2024.27122","article-title":"Testicular germ cell tumors: a review","volume":"333","author":"Singla","year":"2025","journal-title":"JAMA"},{"key":"10.1016\/j.canrad.2025.104712_bib0315","doi-asserted-by":"crossref","first-page":"103224","DOI":"10.1016\/j.critrevonc.2021.103224","article-title":"Serum tumour markers in germ cell tumours: From diagnosis to cure","volume":"159","author":"Pedrazzoli","year":"2021","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.canrad.2025.104712_bib0320","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1200\/JCO.20.03292","article-title":"Survival and new prognosticators in metastatic seminoma: results from the IGCCCG-update consortium","volume":"39","author":"Beyer","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2025.104712_bib0325","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/j.purol.2022.09.009","article-title":"French Afu Cancer Committee Guidelines - Update 2022-2024: testicular germ cell cancer","volume":"32","author":"Murez","year":"2022","journal-title":"Progres Urol"},{"key":"10.1016\/j.canrad.2025.104712_bib0330","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s00330-017-4944-3","article-title":"MRI of the scrotum: Recommendations of the ESUR Scrotal and Penile Imaging Worrking Grroup","volume":"28","author":"Tsili","year":"2018","journal-title":"Eur Radiol"},{"key":"10.1016\/j.canrad.2025.104712_bib0335","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1002\/cncr.11229","article-title":"Sperm banking and rate of assisted reproduction treatment: insights from a 15-year cryopreservation program for male cancer patients","volume":"97","author":"Ragni","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.canrad.2025.104712_bib0340","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1200\/JCO.2009.26.4655","article-title":"Randomized trial of carboplatin versus radiotherapy for stage I seminoma: mature results on relapse and contralateral testis cancer rates in MRC TE19\/EORTC 30982 study (ISRCTN27163214)","volume":"29","author":"Oliver","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2025.104712_bib0345","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.eururo.2022.04.031","article-title":"The G\u00e9tug SEMITEP Trial: de-escalating chemotherapy in good-prognosis seminoma based on fluorodeoxyglucose positron emission tomography\/computed tomography","volume":"82","author":"Loriot","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.canrad.2025.104712_bib0350","doi-asserted-by":"crossref","first-page":"110626","DOI":"10.1016\/j.radonc.2024.110626","article-title":"Radiation therapy for stage IIA\/IIB seminomas: Back to the future?","volume":"202","author":"Le Gu\u00e9velou","year":"2025","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.canrad.2025.104712_bib0355","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1200\/JCO.2014.56.2116","article-title":"Patterns of relapse in patients with clinical stage I testicular cancer managed with active surveillance","volume":"33","author":"Kollmannsberger","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2025.104712_bib0360","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1200\/JCO.2002.07.062","article-title":"Extragonadal germ cell tumors of the mediastinum and retroperitoneum: results from an international analysis","volume":"20","author":"Bokemeyer","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2025.104712_bib0365","doi-asserted-by":"crossref","first-page":"4448","DOI":"10.1200\/JCO.2002.01.038","article-title":"Prognostic factors for relapse in stage I seminoma managed by surveillance: a pooled analysis","volume":"20","author":"Warde","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2025.104712_bib0370","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.eururo.2017.09.025","article-title":"Testicular tumour size and rete testis invasion as prognostic factors for the risk of relapse of clinical stage I Seminoma testis patients under surveillance: a systematic review by the Testicular Cancer Guidelines Panel","volume":"73","author":"Boormans","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.canrad.2025.104712_bib0375","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.eururo.2023.04.010","article-title":"European Association of Urology guidelines on testicular cancer: 2023 update","volume":"84","author":"Patrikidou","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.canrad.2025.104712_bib0380","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1007\/s00345-022-04145-6","article-title":"Testicular germ cell tumours\u2019 clinical stage I:\u00a0comparison of surveillance with adjuvant treatment strategies regarding recurrence rates and overall survival-a systematic review","volume":"40","author":"Ruf","year":"2022","journal-title":"World J Urol"},{"key":"10.1016\/j.canrad.2025.104712_bib0385","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.eururo.2004.01.020","article-title":"Stage II testicular seminoma: patterns of recurrence and outcome of treatment","volume":"45","author":"Chung","year":"2004","journal-title":"Eur Urol"},{"key":"10.1016\/j.canrad.2025.104712_bib0390","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1200\/JCO.2003.06.065","article-title":"Radiotherapy for stages IIA\/B testicular seminoma: final report of a prospective multicenter clinical trial","volume":"21","author":"Classen","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2025.104712_bib0395","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.1007\/s00345-021-03873-5","article-title":"Therapy of clinical stage IIA and IIB seminoma: a systematic review","volume":"40","author":"Heinzelbecker","year":"2022","journal-title":"World J Urol"},{"key":"10.1016\/j.canrad.2025.104712_bib0400","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1093\/annonc\/mdm062","article-title":"Refining the optimal chemotherapy regimen for good-risk metastatic nonseminomatous germ-cell tumors: a randomized trial of the Genito-Urinary Group of the French Federation of Cancer Centers (G\u00e9tug T93BP)","volume":"18","author":"Culine","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1016\/j.canrad.2025.104712_bib0405","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1093\/annonc\/mdu447","article-title":"Radiotherapy or chemotherapy for clinical stage IIA and IIB seminoma: a systematic review and meta-analysis of patient outcomes","volume":"26","author":"Giannatempo","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.canrad.2025.104712_bib0410","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.urolonc.2017.06.051","article-title":"Radiotherapy for stage I and II testicular seminomas: Secondary malignancies and survival","volume":"35","author":"Patel","year":"2017","journal-title":"Urol Oncol"},{"key":"10.1016\/j.canrad.2025.104712_bib0415","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1093\/annonc\/mdt148","article-title":"Neoadjuvant carboplatin before radiotherapy in stage IIA and IIB seminoma","volume":"24","author":"Horwich","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.canrad.2025.104712_bib0420","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1016\/S1470-2045(22)00564-2","article-title":"Single-dose carboplatin followed by involved-node radiotherapy for stage IIA and stage IIB seminoma (SAKK 01\/10): a single-arm, multicentre, phase 2 trial","volume":"23","author":"Papachristofilou","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.canrad.2025.104712_bib0425","doi-asserted-by":"crossref","first-page":"3009","DOI":"10.1200\/JCO.22.00624","article-title":"Surgery in early metastatic seminoma: a phase II trial of retroperitoneal lymph node dissection for testicular seminoma with limited retroperitoneal lymphadenopathy","volume":"41","author":"Daneshmand","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2025.104712_bib0430","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.eururo.2022.10.021","article-title":"Phase 2 single-arm trial of primary retroperitoneal lymph node dissection in patients with seminomatous testicular germ cell tumors with clinical stage IIA\/B (PRIMETEST)","volume":"84","author":"Hiester","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.canrad.2025.104712_bib0435","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1097\/JU.0000000000003697","article-title":"Primary retroperitoneal lymph node dissection for seminoma metastatic to the retroperitoneum","volume":"211","author":"Matulewicz","year":"2024","journal-title":"J Urol"},{"key":"10.1016\/j.canrad.2025.104712_bib0440","doi-asserted-by":"crossref","first-page":"3930","DOI":"10.1200\/JCO.22.01822","article-title":"Primary retroperitoneal lymph node dissection for stage II seminoma: is surgery the new path forward?","volume":"41","author":"Tachibana","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2025.104712_bib0445","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.23.01960","article-title":"Personalized chemotherapy on the basis of tumor marker decline in poor-prognosis germ-cell tumors: updated analysis of the G\u00e9tug-13 phase III trial","author":"Fizazi","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2025.104712_bib0450","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/S0022-5347(06)00508-8","article-title":"Predicting teratoma in the retroperitoneum in men undergoing postchemotherapy retroperitoneal lymph node dissection","volume":"176","author":"Carver","year":"2006","journal-title":"J Urol"},{"key":"10.1016\/j.canrad.2025.104712_bib0455","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1097\/JU.0000000000000318","article-title":"Diagnosis and treatment of early stage testicular cancer: AUA guideline","volume":"202","author":"Stephenson","year":"2019","journal-title":"J Urol"},{"key":"10.1016\/j.canrad.2025.104712_bib0460","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1093\/annonc\/mds628","article-title":"Treatment of testicular intraepithelial neoplasia (intratubular germ cell neoplasia unspecified) with local radiotherapy or with platinum-based chemotherapy: a survey of the German Testicular Cancer Srrtudy Grroup","volume":"24","author":"Dieckmann","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.canrad.2025.104712_bib0465","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1200\/JCO.2002.20.6.1537","article-title":"Effect of graded testicular doses of radiotherapy in patients treated for carcinoma-in-situ in the testis","volume":"20","author":"Petersen","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2025.104712_bib0470","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1038\/sj.bjc.6600771","article-title":"Radiotherapy with 16Gy may fail to eradicate testicular intraepithelial neoplasia: preliminary communication of a dose-reduction trial of the German Testicular Cancer Srrtudy Grroup","volume":"88","author":"Classen","year":"2003","journal-title":"Br J Cancer"},{"key":"10.1016\/j.canrad.2025.104712_bib0475","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.canrad.2013.03.005","article-title":"[Radiotherapy after testicular-sparing surgery for bilateral or monorchide testicular tumours: an innovative approach]","volume":"17","author":"Sargos","year":"2013","journal-title":"Cancer Radiother"},{"key":"10.1016\/j.canrad.2025.104712_bib0480","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.6004\/jnccn.2019.0058","article-title":"Testicular cancer, version 2.2020, NCCN clinical practice guidelines in oncology","volume":"17","author":"Gilligan","year":"2019","journal-title":"J Natl Compr Cancer Netw"},{"key":"10.1016\/j.canrad.2025.104712_bib0485","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1097\/MNM.0000000000000303","article-title":"The role of (18F)-FDG PET\/CT in the management of testicular cancers","volume":"36","author":"Cook","year":"2015","journal-title":"Nucl Med Commun"},{"key":"10.1016\/j.canrad.2025.104712_bib0490","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.annonc.2022.01.002","article-title":"Testicular seminoma and non-seminoma: ESMO-EURACAN Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Oldenburg","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.canrad.2025.104712_bib0495","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1148\/radiol.2541090361","article-title":"Lymphatic metastases from pelvic tumors: anatomic classification, characterization, and staging","volume":"254","author":"McMahon","year":"2010","journal-title":"Radiology"},{"key":"10.1016\/j.canrad.2025.104712_bib0500","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.ijrobp.2008.09.026","article-title":"Pelvic lymph node topography for radiotherapy treatment planning from ferumoxtran-10 contrast-enhanced magnetic resonance imaging","volume":"74","author":"Dinniwell","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2025.104712_bib0505","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1200\/JCO.1999.17.4.1146","article-title":"Optimal planning target volume for stage I testicular seminoma: A Medical Research Council randomized trial. Medical Research Council Testicular Tumor Worrking Grroup","volume":"17","author":"Foss\u00e5","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2025.104712_bib0510","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1200\/JCO.2005.08.003","article-title":"Randomized trial of 30 versus 20Gy in the adjuvant treatment of stage I testicular seminoma: a report on Medical Research Council Trial TE18, European Organisation for the Research and Treatment of Cancer Trial 30942 (ISRCTN18525328)","volume":"23","author":"Jones","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2025.104712_bib0515","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1200\/JCO.2010.30.1044","article-title":"Management of seminomatous testicular cancer: a binational prospective population-based study from the Swedish Norwegian testicular cancer srrtudy grroup","volume":"29","author":"Tandstad","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2025.104712_bib0520","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.radonc.2012.12.002","article-title":"Mapping patterns of nodal metastases in seminoma: Rethinking radiotherapy fields","volume":"106","author":"Paly","year":"2013","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.canrad.2025.104712_bib0525","doi-asserted-by":"crossref","first-page":"555","DOI":"10.3109\/0284186X.2011.564650","article-title":"Bone marrow-sparing intensity-modulated radiation therapy for Stage I seminoma","volume":"50","author":"Zilli","year":"2011","journal-title":"Acta Oncol"},{"key":"10.1016\/j.canrad.2025.104712_bib0530","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1080\/0284186X.2023.2254925","article-title":"Dose comparison of robustly optimized intensity modulated proton therapy (IMPT) vs IMRT and VMAT photon plans for testicular seminoma","volume":"62","author":"R\u00f8nde","year":"2023","journal-title":"Acta Oncol"},{"key":"10.1016\/j.canrad.2025.104712_bib0535","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s00330-014-3437-x","article-title":"Testicular microlithiasis imaging and follow-up: guidelines of the ESUR scrotal imaging subcommittee","volume":"25","author":"Richenberg","year":"2015","journal-title":"Eur Radiol"},{"key":"10.1016\/j.canrad.2025.104712_bib0540","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.euros.2021.02.003","article-title":"Serum small RNA sequencing and miR-375 assay do not identify the presence of pure teratoma at postchemotherapy retroperitoneal lymph node dissection","volume":"26","author":"Lafin","year":"2021","journal-title":"Eur Urol Open Sci"},{"key":"10.1016\/j.canrad.2025.104712_bib0545","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.eururo.2021.06.006","article-title":"Circulating microRNAs, the next-generation serum biomarkers in testicular germ cell tumours: a systematic review","volume":"80","author":"Le\u00e3o","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.canrad.2025.104712_bib0550","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.eururo.2016.07.029","article-title":"Serum levels of microRNA miR-371a-3p: a sensitive and specific new biomarker for germ cell tumours","volume":"71","author":"Dieckmann","year":"2017","journal-title":"Eur Urol"}],"container-title":["Cancer\/Radioth\u00e9rapie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1278321825001283?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1278321825001283?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T07:53:47Z","timestamp":1765526027000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1278321825001283"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":55,"journal-issue":{"issue":"7-8","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S1278321825001283"],"URL":"https:\/\/doi.org\/10.1016\/j.canrad.2025.104712","relation":{},"ISSN":["1278-3218"],"issn-type":[{"value":"1278-3218","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Role of radiotherapy in the management of testicular cancer: Recommendations from the French society for radiation oncology","name":"articletitle","label":"Article Title"},{"value":"Cancer\/Radioth\u00e9rapie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canrad.2025.104712","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Soci\u00e9t\u00e9 fran\u00e7aise de radioth\u00e9rapie oncologique (SFRO). Published by Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104712"}}